Pay in 4 interest-free payments of $5.65 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
[DOI] [PubMed] [Google Scholar] 90.Bouchi R., Nakano Y., Fukuda T., Takeuchi T., Murakami M., Minami I., Izumiyama H., Hashimoto K., Yoshimoto T., Ogawa Y
Zepbound obstructive sleep apnea In December 2024, the FDA approved Zepbound for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity
Lifestyle changes like getting enough sleep, stress reduction, eating a healthy diet, staying well-hydrated, getting regular exercise, going to therapy, and limiting caffeine and alcohol can promote better mental health
When to Speak to Your GP About Mounjaro and Hormone Levels Whilst Mounjaro does not typically affect cortisol levels, there are several situations where you should contact your GP or healthcare professional regarding potential hormonal concerns or medication-related issues: Seek medical advice if you experience: Persistent fatigue or weakness that does not improve with rest and interferes with daily activities, particularly if accompanied by dizziness, low blood pressure, or darkening of the skin (which could suggest adrenal insufficiency, though unrelated to Mounjaro) Unexplained weight changes beyond expected weight loss, especially if accompanied by other symptoms such as excessive thirst, increased urination, or changes in appetite Mood disturbances including persistent low mood, anxiety, or irritability that significantly affects your quality of life Sleep pattern disruptions that are severe or do not resolve, as sleep quality can influence both metabolic health and hormonal balance Signs of hypoglycaemia (low blood sugar) such as trembling, sweating, confusion, or palpitations, particularly if you are taking Mounjaro alongside other diabetes medications like insulin or sulphonylureas Severe or persistent abdominal pain , especially if accompanied by vomiting, which could indicate pancreatitis requiring urgent medical attention Signs of allergic reaction such as rash, itching, swelling, severe dizziness, or difficulty breathing NICE guidance (NG28) recommends regular monitoring for patients on GLP-1 receptor agonists, including assessment of glycaemic control (HbA1c), weight, and tolerability of gastrointestinal side effects
This leads to increased bile acids in the intestinal lumen, which then trigger Takeda G-protein-coupled receptor 5 (TGR5) on L-cells, stimulating the production and release of GLP-1 (Thomas et al., 2009
